Cochlear Limited COH

Australian inflation accelerated to 4% in August, and interest rates now sit at a 15 year high of 4.6%. That mix is putting cost pressure on households while lifting the appeal of resilient sectors. Healthcare often holds up when budgets tighten because treatment is hard to postpone. This article walks through three leading Australian healthcare stocks from a high quality screener that targets robust balance sheets and proven business models. The three stocks in focus below are a starting...

SYDNEY, September 28, 2026--Cochlear today announced the completion of recruitment for the worldwide pivotal trial program evaluating fully implantable hearing technology. Patients across Cochlear’s fully implantable hearing system research programs have experienced more than 1 million hours with their device to date.

This article first appeared on GuruFocus. Cochlear Ltd (CHEOY) recently announced a total dividend of $0.47 per share, with the ex-dividend date set for 2026-09-22. This distribution includes a $0.47 per share cash dividend payable on 2026-11-03.

With markets bracing for higher interest rates in Europe after German import prices and bond yields highlight persistent inflation pressures, patient stock pickers are getting choosier about where to put fresh capital. That is where high quality undervalued stocks come in. Solid balance sheets and good cash flows can matter more when money is not cheap. This article highlights three such stocks from our screener that are worth a closer look. The stocks covered below are just a sample, as the...

With European bond yields pushing toward multi year highs on persistent inflation concerns, investors are again paying close attention to what they are actually paying for future cash flows. Higher discount rates tend to punish overhyped stories and highlight companies whose cash generation already looks attractive. This article walks through three stocks from the Undervalued Stocks Based On Cash Flows screener that appear mispriced against their SWS DCF fair values. The three stocks that...

Despite a modest 2% revenue growth and a 3-point gross margin decline, Cochlear Ltd (CHEOF) advances its innovation pipeline and cost discipline to position for FY27 recovery.

Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, today announces FDA clearance of the new Cochlear® Osia® 3 Sound Processor the newest advancement of the award-winning Osia System.‡ Cochlear's bone conduction hearing solutions are designed to improve hearing outcomes for children and adults with conductive hearing loss, mixed hearing loss and single-sided deafness (SSD).

Summer is a season for social events, backyard barbecues, family vacations, and long conversations with friends. But for the more than 37 million Americans1 with hearing loss, these moments can feel frustrating.

[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Ear Health Market size & share revenue was valued at approximately USD 10.12 Billion in 2025 and is expected to reach USD 10.82 Billion in 2026 and is expected to reach around USD 16.87 Billion by 2035, at a CAGR of 5.7% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Sonova Holdings AG, GN Store Nord A/

May is Better Hearing and Speech Month, a month dedicated to raising awareness about the importance of hearing health. For the millions of people who experience hearing loss in the US, this month serves as a reminder that better hearing is not just about improved communication, it is a critical component of comprehensive health and wellbeing.

In the last week, the Australian market has stayed flat, yet it is up 14% over the past year with earnings forecasted to grow by 12% annually. In this context of steady growth and positive earnings outlook, identifying undervalued stocks can offer potential opportunities for investors seeking to capitalize on market inefficiencies.

Company lowers full-year profit outlook to A$290M--A$330M amid weaker demand and market uncertainty

Cochlear, the global leader in implantable hearing solutions, today launched the Cochlear™ Nucleus® Nexa® System – the world's first and only smart cochlear implant system.

In celebration of International Cochlear Implant Day, Cochlear North America is proud to announce the recipients of the 2026 Cochlear Academic Scholarships. This year, eight exceptional students, who are also recipients of the Cochlear™ Nucleus® System, Cochlear Baha® System, or Cochlear Osia® System, were selected for their academic excellence, leadership, and commitment to making a positive impact in their communities.